Browsing Tag
social anxiety disorder
2 posts
Why Vistagen Therapeutics Inc.’s PALISADE-4 trial may matter more than its cash runway
Find out how Vistagen Therapeutics Inc. is advancing PALISADE-4 with $61.8M in cash and tackling placebo risk in CNS trials. Read the analysis.
Vistagen shares topline PALISADE-3 Phase 3 data for fasedienol in acute social anxiety treatment
Find out how Vistagen’s PALISADE-3 Phase 3 results for fasedienol reshape its social anxiety strategy and investor expectations.